

## EARLY WARNING NEWS RELEASE OF JACOB COHEN

**PHOENIX, AZ, March 20, 2020** – Jacob Cohen, with an address at 9014 N 23rd Ave, Phoenix, AZ 85331, has acquired ownership of 37,808,680 common shares ("**Common Shares**") issued by Hollister Biosciences Inc. (the "**Company**"), a corporation with a head office at 1500 – 1055 West Georgia Street, Vancouver, British Columbia V6E 4N7 Suite 303, 750 West Pender Street, Vancouver, British Columbia, V6C 2T7.

Mr. Cohen acquired 37,808,680 Common Shares in the Company with a deemed value of CDN\$0.20 (the "**Acquisition**") pursuant to a share exchange agreement (the "**Share Exchange Agreement**") dated March 24, 2020 among the Company, Mr. Cohen, and the remaining shareholders of Labtronix, Inc. ("**Labtronix**"). The Share Exchange Agreement provided for the acquisition by the Company of all the issued and outstanding common shares in the capital of Labtronix (the "**Labtronix Shares**") where each Labtronix Share was exchanged for Shares of the Company based on the terms of the Share Exchange Agreement.

Prior to the Acquisition, Mr. Cohen held nil Common Shares in the capital of the Company, which was equal to 0% of the issued and outstanding Common Shares of the Company.

Following the Acquisition, Mr. Cohen holds 37,808,680 Common Shares, which is equal to 20.42% of the issued and outstanding Common Shares of the Company.

Mr. Cohen acquired 37,808,680 Common Shares of the Company for investment purposes. In pursuing such purposes, Mr. Cohen takes a long-term view of its investment. It reserves the right to formulate other plans or make other proposals, and take such actions with respect to its investment in the Company. Depending on market conditions and other factors, Mr. Cohen may acquire additional securities of the Company as Mr. Cohen may deem appropriate, whether in open market purchases, privately negotiated transactions or otherwise. Mr. Cohen may dispose of some or all of such securities. Mr. Cohen may also reconsider and change its plans or proposals relating to the foregoing.

This press release is issued pursuant to early warning requirements of National Instrument 62-104 and National Instrument 62-103, which also requires a report to be filed with regulatory authorities in each of the jurisdictions containing additional information with respect to the foregoing matters (the "**Early Warning Report**"). A copy of the Early Warning Report will be available under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com).